Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder.

NCT00521365 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00521365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00521365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder.
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2008
Completion date
August 31, 2009
Enrollment
88 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar affective psychosis, bipolar disorder, mania, manic disorder, manic state